0001130889 false true 0001130889 2023-11-30 2023-11-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

   

FORM 8-K

   

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 30, 2023

 

CANCER CAPITAL CORP.

(Exact Name if Business Issuer as specified in its Charter)

  

Wyoming   000-32363   91-1803648
(State or other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification Number)

  

2157 S. Lincoln Street, Suite 200

Salt Lake City, Utah 84106

(Address of principal executive offices, including zip code)

 

(801) 323-2395

(Registrant’s telephone number including area code)

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐ Soliciting material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12)

 

  ☐ Pre-commencement communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b))

 

  ☐ Pre-commencement communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    

Securities registered pursuant to Section 12(b) of the Act:

 Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
 Common Stock, par value $0.001                 CNCL   OTC
 
 

 

Item 4.01.  Change in Registrant’s Certifying Accountant.

 

On November 30, 2023, the Board of Directors (the “Board”) of Cancer Capital Corp. (“Cancer Capital” or the “Company) agreed to dismiss the Company’s independent registered public accounting firm, Pinnacle Accountancy Group of Utah (“Pinnacle”), effective as of November 30, 2023. Also on November 30, 2023, the Company engaged the accounting firm of Fruci & Associates (“Fruci”) as the Company’s new independent registered public accounting firm. The Board and the Company’s Audit Committee approved of the dismissal of Pinnacle and the engagement of Fruci.

The reports of Pinnacle on the Company’s financial statements as of and for the two most recent fiscal years ended December 31, 2022, and December 31, 2021, did not contain an adverse opinion or a disclaimer of opinion, nor were such reports qualified or modified as to uncertainty, audit scope or accounting principles.

During Cancer Capital’s most recent fiscal year, since inception and the subsequent interim periods thereto, there were no disagreements between the Company and Pinnacle whether or not resolved, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Pinnacle's satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its report on the Company’s financial statements.

 

Cancer Capital has requested that Pinnacle furnish it with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the above statements. The letter is attached as an exhibit to this Form 8-K.

 

On November 30, 2023, Cancer Capital engaged Fruci as its independent accountant. During the two (2) most recent fiscal years and the interim periods preceding the engagement, the Company did not engage Fruci regarding any of the matters set forth in Item 304(a)(2)(i) or (ii) of Regulation S-B.

 
 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit    
Number   Description
16.1.1   Letter from Pinnacle CPAs, dated February 28, 2024, to the Securities and Exchange Commission regarding statements included in this Form 8-K.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  By: /s/ John W. Peters
  Name:  John W. Peters
  Title: President
   
 

Dated:  November 30, 2023

 

 

 

 

 

v3.24.0.1
Cover
Nov. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 30, 2023
Entity File Number 000-32363
Entity Registrant Name CANCER CAPITAL CORP.
Entity Central Index Key 0001130889
Entity Tax Identification Number 91-1803648
Entity Incorporation, State or Country Code WY
Entity Address, Address Line One 2157 S. Lincoln Street
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Salt Lake City
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84106
City Area Code (801)
Local Phone Number 323-2395
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CNCL
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Cancer Capital (PK) (USOTC:CNCL)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Cancer Capital (PK).
Cancer Capital (PK) (USOTC:CNCL)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Cancer Capital (PK).